2025 Europe Anti-Infective Vaccines Market Revenue Opportunities Report
Description
The 2025 Europe Anti-Infective Vaccines Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Infective Vaccines Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Anti-Infective Vaccines Market in Europe are GlaxoSmithKline (GSK), Sanofi, Merck & Co., and Pfizer Inc. GSK leads with a comprehensive vaccine portfolio including Arexvy for RSV and Shingrix for herpes zoster, holding around 20-25% market share. Sanofi focuses on vaccines for infectious diseases like meningococcal infections, with a strong R&D pipeline supporting 15-20% market share. Merck’s Capvaxive targets pneumococcal strains, competing with Pfizer’s Prevnar 20, and holds 12-15%. Pfizer leads pneumococcal vaccines with Prevnar 20 and boasts a strong global distribution network, controlling about 10-12% of the market.
Additionally, BioNTech and Valneva are notable European biotech firms developing innovative vaccines. BioNTech, known for its mRNA COVID-19 vaccine, is advancing influenza and other infectious disease vaccines in clinical trials. Valneva specializes in vaccines for neglected infectious diseases, including chikungunya and Lyme disease, with ongoing advanced clinical studies and EU regulatory support. These companies complement the market alongside major pharmaceutical leaders by focusing on novel and niche infectious disease vaccines in Europe.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Infective Vaccines Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Anti-Infective Vaccines Market in Europe are GlaxoSmithKline (GSK), Sanofi, Merck & Co., and Pfizer Inc. GSK leads with a comprehensive vaccine portfolio including Arexvy for RSV and Shingrix for herpes zoster, holding around 20-25% market share. Sanofi focuses on vaccines for infectious diseases like meningococcal infections, with a strong R&D pipeline supporting 15-20% market share. Merck’s Capvaxive targets pneumococcal strains, competing with Pfizer’s Prevnar 20, and holds 12-15%. Pfizer leads pneumococcal vaccines with Prevnar 20 and boasts a strong global distribution network, controlling about 10-12% of the market.
Additionally, BioNTech and Valneva are notable European biotech firms developing innovative vaccines. BioNTech, known for its mRNA COVID-19 vaccine, is advancing influenza and other infectious disease vaccines in clinical trials. Valneva specializes in vaccines for neglected infectious diseases, including chikungunya and Lyme disease, with ongoing advanced clinical studies and EU regulatory support. These companies complement the market alongside major pharmaceutical leaders by focusing on novel and niche infectious disease vaccines in Europe.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
